Life science corporations usually forge mergers and acquisition (M&A) offers to get rid of competitors or to develop a pipeline. Not too long ago, there was a spike in M&As, however analysts level in the direction of imminent patent cliffs because the trigger. We have a look at how M&A curiosity impacts revenues and market exclusivity within the healthcare business.
M&A exercise within the healthcare and life sciences sectors has been burgeoning. A report by EY indicated an 81% bounce in M&A investments final yr from 2024, hitting $240 billion. Figures from the primary quarter of this yr recommend that M&As are holding regular at 130 offers, however in comparison with the $106.8 billion that the ultimate quarter of 2025 raked in, it fell to $82.7 billion.
Yale Jen, healthcare fairness Analyst and Managing Director at Laidlaw & Firm, attributes this surge in buyouts to 2 components.
“One is that biotech valuation continues to be in an affordable if not at an overvalued stage. This makes the M&A extra reasonably priced,” stated Jen, who added that many corporations have a “very wholesome steadiness sheet”, which makes M&A way more manageable.
Acquisition premiums fall; file excessive M&As in current occasions
Certainly, acquisition premiums have dropped by 40% in 2025, contemplating these takeover quantities that exceeded valuation numbers had been fairly excessive between 2020 and 2024. This displays a “extra disciplined method to worth creation,” based on a report by McKinsey and Firm. The report revealed that consumers are prioritizing long-term pipeline renewal and platform over transactions that yield mere short-term income highs.
As an illustration, in a area like medtech, the previous yr noticed buying and selling on the lowest valuations since the 2008 monetary disaster. This led administration groups at life science corporations to rethink how they handle their portfolios, spurring M&As, which hit its peak since 2021.
This was largely owed to macro components akin to rising rates of interest and tighter financial insurance policies in addition to what’s come to be often called a post-COVID market correction following the business’s growth with file funding from 2020 to 2022. Furthermore, the valuation hole in synthetic intelligence (AI) has develop into extra obvious. Now, consumers in the life science and healthcare sector are pivoting in the direction of corporations which have included AI. Some that haven’t achieved so have suffered decrease exit multiples.
All this has laid the groundwork for giant pharma to purchase distressed property at a time when patent cliffs are looming. Jen defined that that is the opposite motive why M&As have been elevated; “the necessity for managing the longer term patent cliff for among the main pharma and wish extra worth drivers for a lot of giant biotech corporations,” he identified.
“Some banks have urged that 2026 probably might be the second most energetic yr of M&A in current time,” he stated.
Though M&A has at all times be one of many main exits for biotech buyers, the current elevated actions definitely additional increase this pattern. Firms growing late or early scientific stage merchandise each might profit from this. For late scientific or early industrial stage names, it’s clear that acquirers must complement the wants of their present commercialized illness franchise
Yale Jen, healthcare fairness Analyst and Managing Director at Laidlaw & Firm
The final time M&As spiked was again in 2019, when the business recorded an estimated $328 billion in deal worth, purely from M&As. The blockbuster yr witnessed greater than 480 offers, pushed by buyouts of late-stage pipelines to guard in opposition to patents expiring on the time, a giant one being AbbVie’s monoclonal antibody Humira for treating inflammatory situations, whose patent resulted in 2023. So, AbbVie purchased Irish pharmaceutical and Botox developer Allergan for $63 billion in 2019.
Unsurprisingly, historical past appears to have repeated itself.
When patents expire, it permits for cheaper generics to enter the market. Within the face of impending generic competitors and in an effort to exchange billions in income losses, pharma giants are buying promising biotechs.
What do patent cliffs need to do with it?
An EY report revealed that within the subsequent few years, huge pharmas are anticipated to lose greater than $350 billion in income, significantly from blockbusters which have to date loved market exclusivity.
Take for example, Merck’s $6.7 billion buyout of Terns Prescribed drugs. The massive pharma firm presently faces the approaching lack of market exclusivity for its most cancers drug Keytruda. The monoclonal antibody was greenlit by the U.S. Meals and Drug Administration (FDA) to deal with melanoma in 2014. Solely two years later, it grew to become a blockbuster, surpassing a billion {dollars} in income, and has been authorized to deal with greater than 40 most cancers varieties since.
As Merck’s patent for the antibody pembrolizumab, the energetic ingredient in Keytruda, expires in the direction of the tip of 2028, it purchased Terns, which develops small molecules for most cancers and weight problems, in March. The enormous clocked the potential of TERN‑701, the latter’s tyrosine kinase inhibitor in treating continual myeloid leukemia, a sort of blood most cancers.
This was following the American pharmaceutical’s $10 billion buy of Verona Pharma late final yr. Additionally geared toward plugging the income hole that Keytruda is about to go away, Merck set its sights on Verona’s Ohtuvayre, a small molecule indicated for the upkeep remedy of continual obstructive pulmonary illness (COPD) in adults authorized by the FDA in 2024.
Pfizer’s acquisition of Metsera protects revenues
In addition to Merck, Pfizer acquired metabolic disease-focused Metsera for as much as $10 billion in November. Pfizer simply misplaced the patent to Eliquis, a blood thinner for stopping blood clots. Subsequent yr, will probably be stripped off its patent rights to 2 of its small molecule most cancers medicine, each blockbusters: Ibrance is a CDK4/6 inhibitor for treating breast most cancers and Xtandi is a hormonal remedy for prostate most cancers.
The Metsera buy was a giant deal, contemplating Pfizer needed to combat off Novo Nordisk, which supplied $6.5 billion upfront – greater than Pfizer’s preliminary $4.9 billion upfront provide. Novo, nonetheless, encountered pushback from antitrust regulators, because it had a monopoly in the GLP-1 area – being the developer of famed weight reduction medicine Ozempic/Wegovy – and Metsera was constructing its personal GLP-1 pipeline. It in the end misplaced the bidding conflict in opposition to Pfizer when Metsera went with the latter.
Novo itself simply misplaced the patent to semaglutide, the energetic ingredient in Ozempic and Wegovy in nations like Canada and India this yr, the latter being a fast-growing hub for generics. However it ready to offset this by constructing a patent thicket, having filed lots of of follow-on patents. It additionally licensed United Laboratories’ UBT251 for $5.2 billion from California-based Akero Therapeutics final yr. The candidate is a triple-agonist drug that targets three hormonal pathways, GLP-1, GIP, and glucagon, to probably be simpler than semaglutide.
In the meantime, Bristol Myers Squibb, Johnson & Johnson, and AbbVie, and Regeneron are all coping with patent expirations. Regeneron developed Eylea, which was authorized by the FDA in 2011. The fusion protein is injected into the attention to deal with situations like moist age-related macular degeneration that trigger imaginative and prescient loss. Regeneron sells it within the U.S. whereas Bayer sells it in all places else. In addition to, Regeneron and Sanofi are set to lose the patent of their monoclonal antibody Dupixent for inflammatory situations in 5 years’ time. With Eylea, it seems prefer it has been propped itself up with a patent thicket, as greater than 130 purposes been filed and 91 authorized. As for Dupixent, we must see what the pharma big comes up with to delay the entry of generics.
M&As: Johnson & Johnson and Novartis circumvent losses from patent expirations
Johnson & Johnson has a number of medicine in the marketplace that are on the point of dropping patents, akin to Stelara and the AbbVie-co-owned Imbruvica. Stelara is a monoclonal antibody for inflammatory and autoimmune situations and has had patents expire over the previous few years and in 2026, as biosimilars swarm the market. Imbruvica, a tyrosine kinase inhibitor for blood most cancers, will lose patents this yr and the following, however earnings will stay largely untouched out there due to authorized settlements blocking the launch of generics till 2032.
Nonetheless, the pharma big indulged in M&As final yr, a $14.6 billion buyout of Intra-Mobile Therapies and the $3.05 billion acquisition of Halda Therapeutics. Intra-Mobile’s small molecule Caplyta is the primary and solely FDA-approved remedy for bipolar melancholy as an adjunctive remedy and monotherapy and Halda Therapeutics’ RIPTACs look to be a promising molecular glue know-how to kill most cancers – each favoring J&J’s portfolio.
So as to add to that, Novartis’ Avidity buyout final yr got here as the large pharma’s top-selling coronary heart failure remedy Entresto and bronchial asthma drug Xolair misplaced market exclusivity too.
Jen believes that patent expiration for income cliff throughout the subsequent decade is driving main pharmas to “pull the M&A set off.” He thinks that purchasing up early- and late-stage corporations advantages huge pharmas.
“Though M&A has at all times be one of many main exits for biotech buyers, the current elevated actions definitely additional increase this pattern. Firms growing late or early scientific stage merchandise each might profit from this. For late scientific or early industrial stage names, it’s clear that acquirers must complement the wants of their present commercialized illness franchise. The sooner stage packages primarily to enrich or complement their future pipeline wants,” he stated. “Given the valuation of an M&A occasion at all times contains some M&A premium, many buyers have been properly rewarded in current days.”
Whereas some construct patent thickets surrounding their medicine to maintain generics at bay, most huge pharmas have resorted to M&As to exchange as soon as commercially profitable medicine with new ones, with the hopes that they may deliver them related if no more income. Whether or not chasing the shiny new factor is the most effective wager, we must be careful for.
